Jagsonpal Pharmaceuticals Limited (JAGSNPHARM.NS) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

+83.7%

₹399.33

vs ₹217.42 price

Levered DCF

₹479.15

After debt service

Piotroski score

5 / 9

Average

Altman Z-score

13.66

Safe zone

Rating

Overall 4 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
P/E	29.01×	26.28×	33.47×	28.41×	43.55×	12.25×	2.34×	3.89×
P/B	4.53×	6.09×	4.01×	4.78×	6.28×	1.71×	0.41×	0.67×
P/S	4.35×	5.44×	3.6×	3.21×	3.78×	1.11×	0.29×	0.42×
EV / EBITDA	18.35×	26.28×	23.14×	20.8×	28.19×	6.54×	1.15×	3.28×
Gross margin	63.7%	64.1%	31.3%	60.7%	59.0%	56.9%	64.5%	56.3%
Operating margin	16.9%	16.2%	10.3%	14.5%	11.3%	10.0%	4.7%	5.0%
Net margin	15.0%	20.6%	10.8%	11.3%	8.7%	9.1%	5.0%	4.3%
Current ratio	5.06×	6.22×	10.42×	5.97×	4.04×	2.98×	2.89×	3.46×
Debt / equity	0.03×	0.04×	0.05×	0.04×	0.04×	0.06×	0.04×	0.04×
Interest coverage	47.31×	45.46×	26.29×	83.18×	86.12×	36.59×	14.4×	11.16×
Dividend yield	1.3%	0.9%	1.7%	0.0%	1.3%	1.3%	2.8%	0.9%
Payout ratio	38.7%	23.9%	58.3%	0.0%	55.6%	15.4%	16.6%	9.1%

Key metrics by fiscal year

Metric	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Return on equity	15.6%	23.1%	12.0%	16.8%	14.4%	14.0%	7.1%	6.9%
Return on invested capital	12.6%	13.6%	8.1%	15.7%	12.4%	11.2%	5.1%	6.0%
Return on assets	13.6%	19.9%	10.3%	13.7%	11.2%	10.4%	5.4%	5.3%
Free cash flow yield	3.7%	3.8%	4.6%	6.1%	0.6%	13.3%	20.0%	40.9%
Earnings yield	3.4%	3.8%	3.0%	3.5%	2.3%	8.2%	17.1%	10.3%
Enterprise value	₹12.5B	₹13.4B	₹7.5B	₹7.5B	₹8B	₹1.5B	₹125.7M	₹353.3M
Net debt / EBITDA	-0.03×	-2.34×	-0.12×	-0.14×	-0.7×	-2.35×	-3.06×	-3.23×
Cash conversion cycle (days)	33	39	33	82	70	80	166	151